Sivik Global Healthcare LLC Boosts Stock Holdings in Humana Inc. (NYSE:HUM)

Sivik Global Healthcare LLC increased its position in shares of Humana Inc. (NYSE:HUM) by 33.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,000 shares of the insurance provider’s stock after acquiring an additional 2,500 shares during the period. Sivik Global Healthcare LLC’s holdings in Humana were worth $3,167,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. MQS Management LLC bought a new position in Humana in the third quarter worth about $262,000. Rakuten Securities Inc. raised its holdings in Humana by 2,771.4% in the third quarter. Rakuten Securities Inc. now owns 201 shares of the insurance provider’s stock worth $64,000 after buying an additional 194 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Humana by 0.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 325,409 shares of the insurance provider’s stock worth $103,070,000 after acquiring an additional 2,027 shares during the period. OVERSEA CHINESE BANKING Corp Ltd grew its stake in shares of Humana by 202.5% during the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 2,081 shares of the insurance provider’s stock valued at $656,000 after purchasing an additional 1,393 shares during the period. Finally, GSA Capital Partners LLP increased its position in Humana by 248.6% in the third quarter. GSA Capital Partners LLP now owns 9,120 shares of the insurance provider’s stock worth $2,889,000 after buying an additional 6,504 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of NYSE:HUM traded down $6.73 during midday trading on Thursday, hitting $282.69. The company’s stock had a trading volume of 222,244 shares, compared to its average volume of 1,866,385. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $527.18. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market capitalization of $34.04 billion, a price-to-earnings ratio of 25.67, a PEG ratio of 2.21 and a beta of 0.52. The stock’s 50 day simple moving average is $284.64 and its 200 day simple moving average is $332.14.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. As a group, research analysts anticipate that Humana Inc. will post 15.83 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.25%. Humana’s dividend payout ratio is presently 31.36%.

Wall Street Analyst Weigh In

HUM has been the topic of several recent research reports. Jefferies Financial Group cut Humana from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $519.00 to $253.00 in a report on Monday, October 7th. Truist Financial lowered their target price on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a report on Friday, October 11th. UBS Group reduced their price target on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, October 4th. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and increased their price target for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Finally, Leerink Partners cut Humana from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.